Filing Flows › Aligos Therapeutics (ALGS) › R&D spending
Aligos Therapeutics (ALGS) R&D spending by quarter
Aligos Therapeutics' R&D spending was $18.9M in Q3 2026 (third quarter 2026), -19% from Q1 2026. Over the last 7 quarters it ranged from $14.0M (Q2 2025) to $23.9M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $18.9M | -19% | -21% |
| Q1 2026 | $23.4M | +37% | +61% |
| Q4 2025 | $17.0M | -29% | +6% |
| Q3 2025 | $23.9M | +71% | — |
| Q2 2025 | $14.0M | -4% | — |
| Q1 2025 | $14.5M | -10% | — |
| Q4 2024 | $16.0M | — | — |
Q3 2026 at a glance
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aligos Therapeutics' R&D spending?
Aligos Therapeutics' R&D spending was $18.9M in Q3 2026 (third quarter 2026), -19% from Q1 2026.
How has Aligos Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $14.0M (Q2 2025) to $23.9M (Q3 2025).